Fauci Apologizes For UK V US Vaccine Comments: Not Better, Not Worse, Just Different
Top US Immunologist Says He Didn’t Mean To Accuse MHRA Of ‘Sloppiness’
Executive Summary
The UK’s rapid authorization of the Pfizer/BioNTech COVID-19 vaccine has sparked a public debate over regulatory processes at some of the world’s key regulatory bodies.
You may also be interested in...
Former FDA Commissioners Muse On Vaccine Surveillance – And The Next Operation Warp Speed
On the question of whether the US review of COVID vaccines is moving too slow compared to the UK, 'This is a lot of falderol,' Califf said.
CBER Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.
Experts Defend UK Agency Over Rapid Authorization Of COVID-19 Vaccine
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.